Dr. Gammans’ Peer Reviewed Articles

Dr. Gammans Selected Peer-Reviewed Publications:

1) Traynor AM, Gordon MS, Alberti D, Mendelson DS, Munsey MS, Wilding G, Gammans, RE, Read WL. A

dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest

New Drugs. 2009 May 13. [Epub ahead of print] PubMed PMID: 19434370.

2) Tirschwell DL, Longstreth WT Jr, Becker KJ, Gammans RE Sr, Sabounjian LA, Hamilton S, Morgenstern

LB. Shortening the NIH Stroke scale for use in the prehospital setting. Stroke. 2002 Dec;33(12):2801-6.

PubMed PMID: 12468773.

3) Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D’Orlando KJ, Gammans, RE, Nutt DJ. Crossover

trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 2001

Sep;15(3):205-8. PubMed PMID: 11565630.

4) Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999 Dec;30(12):2592-7. PubMed PMID:

10582983.

5) Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of

citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. 1997 Sep;49(3):671-8.

PubMed PMID: 9305321.

6) Barbhaiya RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, Gammans RE. Disposition

kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol. 1994;46(1):41-7. PubMed PMID: 7911763.

7) Shyu WC, Mayol RF, Pfeffer M, Pittman KA, Gammans RE, Barbhaiya RH. Biopharmaceutical evaluation

of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos. 1993

Jul;14(5):371-9. PubMed PMID: 8218955.

8) Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC,

Smith WT, Rickels K. Use of buspirone in patients with generalized anxiety disorder and coexisting

depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology.

1992;25(4):193-201. PubMed PMID: 1454160.

9) Böhm C, Robinson DS, Gammans RE. Buspirone therapy for elderly patients with anxiety or depressive

neurosis. J Clin Psychiatry. 1990 Jul;51(7):309. PubMed PMID: 2195007.

10) Robinson DS, Rickels K, Feighner J, Fabre LF Jr, Gammans RE, Shrotriya RC, Alms DR, Andary JJ,

Messina ME. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of

buspirone in the treatment of depression. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):67S-76S.

PubMed PMID: 2198303.

11) Böhm C, Robinson DS, Gammans RE, Shrotriya RC, Alms DR, Leroy A, Placchi M. Buspirone therapy in

anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):47S-51S.

PubMed PMID: 2198301.

12) Böhm C, Placchi M, Stallone F, Gammans RE, Alms DR, Shrotriya RC, Robinson DS. A double-blind

comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice

setting. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):38S-42S. PubMed PMID: 1973939.

13) Gammans RE, Westrick ML, Shea JP, Mayol RF, LaBudde JA. Pharmacokinetics of buspirone in elderly

subjects. J Clin Pharmacol. 1989 Jan;29(1):72-8. PubMed PMID: 2708551.

14) Caccia S, Vigano GL, Mingardi G, Garattini S, Gammans RE, Placchi M, Mayol RF, Pfeffer M. Clinical

pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988

Mar;14(3):171-7. PubMed PMID: 3370902.

15) Bartek MJ, Mayol RF, Boarman MP, Gammans RE, Gallo DG. Analysis of encainide and metabolites in

plasma and urine by high-performance liquid chromatography. Ther Drug Monit. 1988;10(4):446-52.

PubMed PMID: 3144068.